SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
JANUARY 10, 2006
Date of Report
(Date of earliest event reported)
NEW BRUNSWICK SCIENTIFIC CO., INC.
(Exact Name of Registrant as Specified in Charter)
NEW JERSEY 0-6994 22-1630072
State or Other
Jurisdiction of (Commission File Number) (IRS Employer
Incorporation) Identification No.)
44 TALMADGE ROAD, EDISON, NJ 08818-4005
(Address of Principal Executive Offices) (ZIP Code)
Registrant's telephone number, including area code: (732) 287-1200
(Former Name or Former Address, if Changed Since Last Report)
1
Item 5.02 Appointment of Principal Officers
NEW BRUNSWICK SCIENTIFIC CO., INC.
P.O. Box 4005 - 44 Talmadge Road - Edison, NJ 08818-4005 U.S.A.
CONTACTS:
James Orcutt Matthew J. Dennis, CFA
President & Chief Operating Officer NBS Investor Relations
New Brunswick Scientific Co., Inc. Clear Perspective Group, LLC
732.650.2525 440.353.0552
jorcutt@nbsc.com mdennis@cpg-llc.com
FOR IMMEDIATE RELEASE
NEW BRUNSWICK SCIENTIFIC NAMES NEW CHIEF FINANCIAL OFFICER
EDISON, NEW JERSEY, JANUARY 10, 2006-New Brunswick Scientific Co., Inc. (NBS)
(NASDAQ: NBSC), a leading provider of a comprehensive line of research equipment
and scientific instrumentation for use in the life science industry, today
announced that Thomas E. Bocchino, 46, has been appointed vice president,
Finance and chief financial officer, replacing Samuel Eichenbaum who, as
previously announced, will retire as an employee of the company effective
January 31, 2006.
For the past five years, Bocchino was chief financial officer of IVC Industries
Inc., now a subsidiary of Inverness Medical Innovations, Inc., with
responsibilities for financial reporting, internal control and Sarbanes-Oxley
compliance. He served as IVC's controller from 1990 to 1997.
Prior to joining IVC, Bocchino gained industry experience through increasingly
responsible positions with Rheem Manufacturing Co.'s Container Division, Jazz
Photo Corp. and in public accounting. Bocchino earned his bachelor's degree in
Business Administration from the University of Dayton. He is a Certified Public
Accountant in the State of New Jersey.
Commenting on the new hire, NBS co-founder and Chairman David Freedman stated,
"We are pleased to welcome Tom to our company and look forward to his
contribution toward achievement of our strategic objectives and the enhancement
of shareholder value.
2
"We also would like to take this opportunity to commend Sam Eichenbaum for his
21 years of dedicated service to our company, and wish him much happiness in his
retirement."
To be added to New Brunswick Scientific's e-mail distribution list, please click
on the link below:
http://www.clearperspectivegroup.com/clearsite/nbsc/emailoptin.html
- -------------------------------------------------------------------
ABOUT NEW BRUNSWICK SCIENTIFIC
New Brunswick Scientific Co., Inc., is a leading global provider of a
comprehensive line of research equipment and scientific instrumentation for use
in the life science industry. The Company's products are used in the creation,
maintenance and control of physical and biochemical environments required for
the growth, detection and storage of microorganisms for medical, biological and
chemical applications, as well as environmental research and commercial product
development. NBS is a forerunner in the research and development of pioneering
equipment to meet the challenges of new areas of advancement in life science.
Established in 1946, New Brunswick Scientific is headquartered in Edison, New
Jersey, with sales and distribution facilities strategically located in the
United States, Europe and Asia. For more information, please visit www.nbsc.com
------------.
This press release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements may be identified by words such as "expects," "anticipates,"
"intends," "plans," "believes," "seeks," "estimates," "will" or words of similar
meaning and include, but are not limited to, statements about the expected
future business and financial performance of the Company. The forward-looking
statements involve a number of risks and uncertainties, including but not
limited to: changes in economic conditions, demand for the Company's products,
pricing pressures, intense competition in the industries in which the Company
operates, the need for the Company to keep pace with technological developments
and respond in a timely manner to changes in customer needs, the Company's
dependence on third-party suppliers, the effect on foreign sales of currency
fluctuations, acceptance of new products, the labor relations of the Company and
its customers and other factors identified in the Company's Securities and
Exchange Commission filings. Forward-looking statements are based on
management's current expectations and assumptions, which are inherently subject
to uncertainties, risks and changes in circumstances that are difficult to
predict. Actual outcomes and results may differ materially from these
expectations and assumptions due to changes in global political, economic,
business, competitive, market, regulatory and other factors. The Company
undertakes no obligation to publicly update or review any forward-looking
information, whether as a result of new information, future developments or
otherwise.
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant had duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
NEW BRUNSWICK SCIENTIFIC CO., INC.
Date: January 10, 2006 by: /s/ David Freedman
- ----------------------------------------------------
David Freedman
Chairman and
Chief Executive Officer
4